Clear Scientific Participates in World Health Expo Dubai 2026, Strengthening Global Life Sciences Connections

Dubai | February 2026

Clear Scientific, represented by Peter Howe, Co-Founder and CFO participated in the World Health Expo (WHX) Dubai 2026, a global healthcare platform focusing on life sciences innovation in the Middle East North Africa (MENA) region. This conference underscores the growing importance of cross border engagement between the Middle East and the Americas in accelerating life sciences investment, commercialization, and innovation. 

Clear Scientific participated in the launch of the Miami Life Sciences Investment Delegation in partnership with the Miami Dade Beacon Council and the Miami–Dubai Chamber of Commerce to foster international partnerships and investment in health innovation. 

Clear Scientific held productive discussions regarding the potential use of the company’s therapeutics to address public health needs in the MENA region, engaging with key stakeholders including first responders, hospital systems, regulators and funding sources. The company met with the two key first responder service providers in the United Arab Emirates, representing the vast majority of the active ambulances in the country and several major regional hospital systems with hospitals located throughout MENA.  The company also held introductory meetings with Department of Health and Emirates Drug Establishments (EDE). 

This participation underscores Clear Scientific’s commitment to advancing science-driven health solutions globally. 

About Clear Scientific 

Clear Scientific was co-founded in March 2019 by Professor George M. Whitesides of Harvard University with technology licensed from Massachusetts General Hospital and the University of Maryland. 

Clear Scientific is pioneering a new paradigm for treatment of conditions and diseases that involve an excess of specific compounds in the body. The company is developing highly selective, small molecule sequestrants that bind, inactivate, and rapidly clear these excess compounds from the body.  Clear Scientific receives funding from the National Institutes of Health (NIH) / National Institute on Drug Abuse (NIDA) and is working with their network of medical and academic professionals. 

About CS-1103 

CS-1103 is a first-in-class injectable small molecule sequestrant that binds and inactivates target compounds, rapidly reversing their effects and accelerating their clearance into urine. Clear Scientific is initially targeting methamphetamine, fentanyl and cocaine overdose, representing close to 95% of drug fatalities in the US. The Company’s pipeline includes indications in substance use disorder, central nervous system (CNS) and metabolic diseases amongst others. CS-1103 is investigational and has not been approved by any health authority.

For more information, visit https://www.clearsci.com.